BRISTOL MYERS SQUIBB CO
CELG-RIDrugs in Pipeline
288
Phase 3 Programs
117
Upcoming Catalysts
25
Next Catalyst
This month
Market Overview
Stock performance and key metrics
26 upcoming, 1 past
Corticosteroid Phase 2 Est. Readout
Estimated primary completion for Corticosteroid trial (NCT04477629) in Heart Transplantation. Topline data typically follows completion by weeks to months.
Source25 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Opdivo
Renal Cell Carcinoma
Xanomeline/Trospium Chloride
Mania
Efavirenz
HIV Infections
Lenalidomide
Multiple Myeloma
Nelfinavir mesylate
HIV Infections
Xanomeline Enteric Capsule
Alzheimer Disease
BMS-790052 (NS5A Replication Complex Inhibitor)
Hepatitis C
Tanespimycin
Advanced Malignancies
DCV 3DAA
Hepatitis C Virus Infection
Brivanib
Hepato Cellular Carcinoma (HCC)
BMS-986278
Idiopathic Pulmonary Fibrosis
Sofosbuvir
Hepatitis C
Atazanavir + ritonavir + tenofovir + nucleoside
HIV Infections
BMS-986504
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Sorivudine
HIV Infections
Epoetin Alfa
Myelodysplastic Syndromes
KarX-EC
Alzheimer's Disease
Relatlimab
Advanced Gastric Cancer
Pumitamig
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
Rheumatoid Arthritis
Atazanavir + Ritonavir
Human Immunodeficiency Virus (HIV) Infections
Pegylated-Interferon-lambda
Hepatitis C Virus
Adefovir
Hepatitis B, Chronic
Cyclosporin A
Renal Transplantation
Daclatasvir
Hepatitis C Infection
BMS-936558
Unresectable or Metastatic Melanoma
Luspatercept
Myelodysplastic Syndromes
Acetylsalicylic acid
Atrial Fibrillation
BMS-986205
Advanced Cancer
SAR302503
Hematopoietic Neoplasm
abatacept (ABA)
Ulcerative Colitis
pegIFNα-2b
Hepatitis C Virus Infection
Oral Azacitidine
Myelodysplastic Syndromes
Abatacept subcutaneous
Polymyositis
Ozanimod
Multiple Sclerosis, Relapsing-Remitting
Atazanavir (immediate switch)
HIV Infections
Atazanavir/Ritonavir
HIV
Videx EC
HIV Infections
Apixaban
Lymphoma
Irbesartan monotherapy
Hypertension
Dasatinib
Multiple Indications Cancer
Apremilast
Psoriatic Arthritis
Clopidogrel (SR25990)
Heart Defects, Congenital
Pemetrexed
Non-Small Cell Lung Cancer
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)
Rheumatoid Arthritis
Warfarin
Coronary Artery Bypass Grafting
Tenofovir
Chronic Hepatitis B
Atazanavir
HIV Infections
Lamivudine/Zidovudine
HIV Infections
Abatacept
Rheumatoid Arthritis
Nab-paclitaxel/Paclitaxel
Breast Neoplasms
Atazanavir Sulphate
HIV
Zidovudine (ZDV)
HIV Infections
Telaprevir
Hepatitis C
Pomalidomide
Multiple Myeloma
Cyclosporine (CsA)
Kidney Transplantation
Xanomeline and Trospium Chloride Capsules
Schizophrenia
MDX-010 (anti-CTLA4) monoclonal antibody
Melanoma
Ribavirin
Hepatitis C
Aripiprazole oral product
Pervasive Developmental Disorder
Peg-interferon Alfa-2a
Hepatitis C Virus
Paclitaxel and carboplatin
Carcinoma, Non-Small-Cell Lung
Pegylated interferon lambda (pegIFNλ)
Hepatitis C Virus (HCV)
Iza-bren
Urothelial Cancer
vinflunine
Transitional Cell Carcinoma
Abatacept SC
Sjögren's Syndrome
rHuPH20
Melanoma
Irbesartan
Atrial Fibrillation
stavudine, efavirenz, lamivudine
HIV Infections
Stavudine
HIV Infections
Entecavir
Hepatitis B, Chronic
Elotuzumab
Multiple Myeloma
DCV/ASV/BMS-791325
Hepatitis C Virus
Subcutaneous (SC) Abatacept
Rheumatoid Arthritis (RA)
Mezigdomide
Relapsed or Refractory Multiple Myeloma
Peginterferon Alfa-2a
Hepatitis C
Subcutaneous Abatacept
Rheumatoid Arthritis
pexacerfont
Generalized Anxiety Disorder
Bempegaldesleukin
Bladder Cancer
Xanomeline/Trospium Chloride Capsule
Alzheimer Disease
current antiretroviral regimen
HIV Infection
ONO-4538
Non-Small Cell Lung Cancer
Iberdomide
Multiple Myeloma
emtricitabine, FTC (drug)
HIV Infections
Muraglitazar
Metabolics Diabetes Nos
Didanosine
HIV Infections
FOLFOX or
Colorectal Cancer
Deucravacitinib
Psoriatic Arthritis
Apixaban 5 MG
Cancer-associated Thrombosis
Mavacamten
Cardiomyopathy, Hypertrophic
clopidogrel (SR25990C)
Atrial Fibrillation
Cyclosporine A
Renal Transplant
Atazanvir/ritonavir + efavirenz
HIV Infections
Belatacept
Renal Transplantation
Lithium
Bipolar Disorder Type I With Mania
Asunaprevir (ASV)
Hepatitis C Virus
Methotrexate (MTX)
Rheumatoid Arthritis (RA)
Irbesartan/HCTZ
Hypertension
PEG-Interferon alfa 2a
Hepatitis C, Genotype 1
Peginterferon Lambda-1a
Hepatitis C Virus (HCV)
atazanavir/ritonavir +2 NRTIs (immediate Switch Group)
HIV Infections
Double-blind Abatacept
Rheumatoid Arthritis
Atazanavir powder
HIV Infections
Asunaprevir
Hepatitis C
Enteric Coated Mycophenolate Sodium
Renal Allograft Recipients
BMS-986165
Psoriasis
KarXT
Alzheimer Disease
BMS-986353
Systemic Sclerosis
Docetaxel/Paclitaxel
Esophageal Cancer
idecabtagene vicleucel
Multiple Myeloma
Warfarin titrated to an INR of 2.5-3.0
Heart Failure
Glucovance (metformin HCl/glyburide)
Diabetes Mellitus, Non-Insulin-Dependent
ATV
HIV Infections
Topical Dapsone 5% Gel
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have
Atazanavir/ritonavir monotherapy
HIV-1 Infection
DCV
Hepatitis C
Atazanavir+ritonavir
HIV Infections
Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa
Breast Cancer
DUAL
Cirrhosis
Oncovin
Peripheral T Cell Lymphoma
CRS-207
Previously Treated Metastatic Adenocarcinoma of the Pancreas
IPI-549 (eganelisib)
Bladder Cancer
Degarelix
Prostate Cancer
CC-486 300
Non-Small Cell Lung Cancer
lulizumab pegol
Living-Donor Kidney Transplant
ECF
Esophageal Cancer
lisocabtagene maraleucel
Lymphoma, Non-Hodgkin
Xanomeline and trospium chloride (KarXT)
SCHIZOPHRENIA 1 (Disorder)
pemetrexed disodium
Lung Cancer
Androgen Deprivation Therapy
Hormone Sensitive Prostate Cancer
Plinabulin
Lung Cancer
GM-CSF (Sargramostim)
Ovarian Cancer
Dasatinib Maximum Tolerated Dose
Non-Hodgkin's Lymphoma
Cetuximab,Paclitaxel, Carboplatin
Esophageal Cancer
UV1 vaccine + leukine
Cancer
CC-97540
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
HuMax-IL8
Head and Neck Squamous Cell Carcinoma
golcadomide
Follicular Lymphoma Stage II
xenon gas
Hypoxic Ischaemic Encephalopathy
BMS- 986205
Endometrial Adenocarcinoma
GVAX Pancreas Vaccine
Pancreatic Cancer
Bleomycin
Hodgkin Lymphoma
Varicella Zoster Vaccine
Herpes Zoster
IDO1 Inhibitor BMS-986205
Lip
BMS-986249
Advanced Cancer
Estramustine
Prostate Cancer
Fedratinib Pill
Myeloproliferative Neoplasm
pTVG-HP
Prostate Cancer
SipT Treatment
Prostate Cancer
Oral apixaban
Gynecologic Cancer
Vincristine Sulfate
Aggressive Non-Hodgkin Lymphoma
Drug Abilify
Depression
Neoantigen Dendritic Cell Vaccine
Hepatocellular Carcinoma
Pegylated Interferon alpha-2a
Hepatitis C Virus Genotype 4 Infection
Corticosteroid
Heart Transplantation
mFOLFIRINOX
Phase 2 Study
Chemotherapy, albumin-bound paclitaxel
Glioblastoma
Erbitux, Paclitaxel & Carboplatin
Cancer of Head and Neck
Corticosteroid: Betamethasone
Melanoma
Paclitaxel, vinorelbine, cisplatin
NSCLC Stage IIIB
pilimumab
Advanced Stage Non-small Cell Lung Cancer
roginolisib
Peripheral T Cells Lymphoma (PTCL)
Nulojix (Belatacept)
Renal Transplant
Clopidogrel 75 mg daily
Atherosclerosis
Testosterone cypionate
Castration-resistant Prostate Cancer
Dasatinib and Paclitaxel
Breast Cancer
TACE
Carcinoma, Hepatocellular
Low dose doxorubicin
Metastatic Breast Cancer
Tenofovir/emtricitabine
HIV Infections
gavo-cel
Mesothelioma
PD-1 blocking antibody
Nasopharyngeal Carcinoma
abatacept (Orencia ®)
Urticaria
BMS-754807
Breast Cancer
Aurexis®
Staphylococcus Aureus Bacteremia
Vitamin K Antagonist (VKA)
Thrombosis
CXL-1020
Heart Failure
Oral Taxane
Non-small Cell Lung Cancer
BMS-986253
Cancer
Temozolomide 50mg/m2/day
Adenocarcinoma - GEJ
BMS-986322
Psoriasis
BMS-986490
Advanced Solid Tumors
MYK-491
Heart Failure With Reduced Ejection Fraction
PSI-7977
Chronic Hepatitis C
200 mg INX-08189 Fasted
Hepatitis C
unfractionated heparin (UFH)
Antithrombotic
MORAb-202
Neoplasms, Ovarian
BMS-986523
Advanced Solid Malignancies
BMS-986259
Acute Decompensated Heart Failure
BMS-986036
Non-Alcoholic Steatohepatitis
BMS-823778
Dyslipidemia
Lirilumab
Non-Hodgkin's Lymphoma
MDX-1100
Rheumatoid Arthritis
BMS-986213
Advanced Solid Tumors
Trametinib
Cancer
BMS-986158
Myelofibrosis
BMS-986020
Idiopathic Pulmonary Fibrosis
BMS-830216
Obesity
Strata 1 CXL-1020
Heart Failure
carboplatin + irinotecan
Neoplasms
BMS-986340
Cervical Cancer
BMS-986446
Alzheimer Disease, Early Onset
SAR302503 (TG101348)
Myelofibrosis
HNO Donor
Heart Failure
BMS-986435
Heart Failure
ixabepilone
Esophageal Cancer
BMS-790052
Hepatitis C Infection
BMS-986142
Rheumatoid Arthritis
CC-92480
Multiple Myeloma
Cabiralizumab
Advanced Pancreatic Cancer
CXL-1427
Heart Failure
Peginterferon α-2a
Hepatitis C
BMS-986156
Solid Tumors
MDX-010 / MDX-010 + Docetaxel
Prostate Cancer
Lamivudine
Hepatitis B Virus
BMS-986458
Relapsed/Refractory Non-Hodgkin Lymphoma
Thymoglobulin
Kidney Transplantation
BMS-690514
Non-Small-Cell Lung Carcinoma
Ritonavir
HIV Infections
Abatacept (BMS-188667)
Rheumatoid Arthritis
BMS-986288
Advanced Cancer
BMS-650032
Hepatitis C Virus
CC-486
Leukemia, Myeloid, Acute
BMS-986141
Thrombosis
Aurexis® (tefibazumab)
Staphylococcus Aureus
Cabazitaxel
Prostate Cancer
Pegylated Interferon Lambda
Hepatitis C
Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)
HIV Infections
BMS-986369
Relapsed or Refractory T-cell Lymphomas
5-fluorouracil (5-FU)
Colorectal Cancer
Peginterferon alpha-2a
Hepatitis C Infection
Exemestane + Dasatinib
Breast Cancer
Dasatinib 100 mg
Breast Cancer
MDX-010
Breast Cancer
BMS-986004 75 mg IV
Immune Thrombocytopenic Purpura
Vemurafenib
Melanoma
KOS-1584
Non-Small Cell Lung Cancer
INX-08189 50 mg
Healthy
Pegylated-interferon alfa-2a
Chronic Hepatitis C
BMS-708163
Alzheimer's Disease
BMS-954561
Diabetic Peripheral Neuropathic Pain
CCR2 Antagonist
Type 2 Diabetes
BMS-986012 (anti-fucosyl-GM1)
Small Cell Lung Cancer
BMS-986482
Advanced Solid Tumors
BMS-791325
Hepatitis C Virus
BMS-562086
Irritable Bowel Syndrome
Elotuzumab (BMS-901608)
Multiple Myeloma
BMS-986012
Extensive-stage Small Cell Lung Cancer
BMS-833923
Leukemia
BMS-986165 Dose A
Active Psoriatic Arthritis
BMS-986315
Advanced Solid Tumor
BMS-986470
Anemia, Sickle Cell
BMS-790052 (NS5A Inhibitor)
Hepatitis C
BMS-986525
Relapsed/Refractory Small Cell Lung Cancer
BMS-813160
Advanced Cancer
BMS-914392
Atrial Fibrillation
branebrutinib
Autoimmune Disorder
Megestrol acetate
Anorexia
BMS-582949
Vascular Diseases
Cobimetinib
Microsatellite Unstable Colorectal Cancer
Afimetoran
Systemic Lupus Erythematosus
BMS-820836
Depression
pegIFN
Hepatitis B Virus
Thalidomide
Relapsed and/or Refractory Multiple Myeloma
BMS-986449
Advanced Solid Tumors
Pegylated interferon alfa-2a
Hepatitis C Virus
Cyclosporine
Graft Rejection
Imzokitug
Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Anti-CD137 (4-1BB) (BMS-663513)
Melanoma
BMS-777607
Advanced Solid Tumors
Fedratinib
Primary Myelofibrosis
BMS-986231
Cardiac Failure
BMS-908662
Colorectal Cancer
BMS-770767
Diabetes Type 2
BMS-986507
Lung Cancer
BMS-986263
Hepatic Cirrhosis
INX-08189 50 mg QD X 5 days
Healthy
BMS-936557 (Anti-IP-10 Antibody)
Crohn's Disease
brivanib (active)
Hepatocellular Carcinoma (HCC)
MDX-010 (CTLA-4)
Melanoma
BMS-986207
Broad Solid Tumor
BMS-986517
Solid Tumours
Simeprevir
Hepatitis C Virus
CXCR1/2 Inhibitor SX-682
Metastatic Colon Adenocarcinoma
BMS-986489
Limited Stage Small Cell Lung Cancer
Carfilzomib
Multiple Myeloma
nab-Paclitaxel
Non-Small Cell Lung Cancer
Dasatinib (BMS-354825)
Leukemia
APX005M
Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Opdivo | Approved | Renal Cell Carcinoma | - | - |
Xanomeline/Trospium Chloride | Phase 3 | Mania | - | - |
Efavirenz | Phase 3 | HIV Infections | - | - |
Lenalidomide | Phase 3 | Multiple Myeloma | - | - |
Nelfinavir mesylate | Phase 3 | HIV Infections | - | - |
Xanomeline Enteric Capsule | Phase 3 | Alzheimer Disease | - | - |
BMS-790052 (NS5A Replication Complex Inhibitor) | Phase 3 | Hepatitis C | - | - |
Tanespimycin | Phase 3 | Advanced Malignancies | - | - |
DCV 3DAA | Phase 3 | Hepatitis C Virus Infection | - | - |
Brivanib | Phase 3 | Hepato Cellular Carcinoma (HCC) | - | - |
BMS-986278 | Phase 3 | Idiopathic Pulmonary Fibrosis | - | - |
Sofosbuvir | Phase 3 | Hepatitis C | - | - |
Atazanavir + ritonavir + tenofovir + nucleoside | Phase 3 | HIV Infections | - | - |
BMS-986504 | Phase 3 | Metastatic Non-small Cell Lung Cancer With MTAP Deletion | - | - |
Sorivudine | Phase 3 | HIV Infections | - | - |
Epoetin Alfa | Phase 3 | Myelodysplastic Syndromes | - | - |
KarX-EC | Phase 3 | Alzheimer's Disease | - | - |
Relatlimab | Phase 3 | Advanced Gastric Cancer | - | - |
Pumitamig | Phase 3 | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | - | - |
Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | Phase 3 | Rheumatoid Arthritis | - | - |
Atazanavir + Ritonavir | Phase 3 | Human Immunodeficiency Virus (HIV) Infections | - | - |
Pegylated-Interferon-lambda | Phase 3 | Hepatitis C Virus | - | - |
Adefovir | Phase 3 | Hepatitis B, Chronic | - | - |
Cyclosporin A | Phase 3 | Renal Transplantation | - | - |
Daclatasvir | Phase 3 | Hepatitis C Infection | - | - |
BMS-936558 | Phase 3 | Unresectable or Metastatic Melanoma | - | - |
Luspatercept | Phase 3 | Myelodysplastic Syndromes | - | - |
Acetylsalicylic acid | Phase 3 | Atrial Fibrillation | - | - |
BMS-986205 | Phase 3 | Advanced Cancer | - | - |
SAR302503 | Phase 3 | Hematopoietic Neoplasm | - | - |
abatacept (ABA) | Phase 3 | Ulcerative Colitis | - | - |
pegIFNα-2b | Phase 3 | Hepatitis C Virus Infection | - | - |
Oral Azacitidine | Phase 3 | Myelodysplastic Syndromes | - | - |
Abatacept subcutaneous | Phase 3 | Polymyositis | - | - |
Ozanimod | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
Atazanavir (immediate switch) | Phase 3 | HIV Infections | - | - |
Atazanavir/Ritonavir | Phase 3 | HIV | - | - |
Videx EC | Phase 3 | HIV Infections | - | - |
Apixaban | Phase 3 | Lymphoma | - | - |
Irbesartan monotherapy | Phase 3 | Hypertension | - | - |
Dasatinib | Phase 3 | Multiple Indications Cancer | - | - |
Apremilast | Phase 3 | Psoriatic Arthritis | - | - |
Clopidogrel (SR25990) | Phase 3 | Heart Defects, Congenital | - | - |
Pemetrexed | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB) | Phase 3 | Rheumatoid Arthritis | - | - |
Warfarin | Phase 3 | Coronary Artery Bypass Grafting | - | - |
Tenofovir | Phase 3 | Chronic Hepatitis B | - | - |
Atazanavir | Phase 3 | HIV Infections | - | - |
Lamivudine/Zidovudine | Phase 3 | HIV Infections | - | - |
Abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
Nab-paclitaxel/Paclitaxel | Phase 3 | Breast Neoplasms | - | - |
Atazanavir Sulphate | Phase 3 | HIV | - | - |
Zidovudine (ZDV) | Phase 3 | HIV Infections | - | - |
Telaprevir | Phase 3 | Hepatitis C | - | - |
Pomalidomide | Phase 3 | Multiple Myeloma | - | - |
Cyclosporine (CsA) | Phase 3 | Kidney Transplantation | - | - |
Xanomeline and Trospium Chloride Capsules | Phase 3 | Schizophrenia | - | - |
MDX-010 (anti-CTLA4) monoclonal antibody | Phase 3 | Melanoma | - | - |
Ribavirin | Phase 3 | Hepatitis C | - | - |
Aripiprazole oral product | Phase 3 | Pervasive Developmental Disorder | - | - |
Peg-interferon Alfa-2a | Phase 3 | Hepatitis C Virus | - | - |
Paclitaxel and carboplatin | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Pegylated interferon lambda (pegIFNλ) | Phase 3 | Hepatitis C Virus (HCV) | - | - |
Iza-bren | Phase 3 | Urothelial Cancer | - | - |
vinflunine | Phase 3 | Transitional Cell Carcinoma | - | - |
Abatacept SC | Phase 3 | Sjögren's Syndrome | - | - |
rHuPH20 | Phase 3 | Melanoma | - | - |
Irbesartan | Phase 3 | Atrial Fibrillation | - | - |
stavudine, efavirenz, lamivudine | Phase 3 | HIV Infections | - | - |
Stavudine | Phase 3 | HIV Infections | - | - |
Entecavir | Phase 3 | Hepatitis B, Chronic | - | - |
Elotuzumab | Phase 3 | Multiple Myeloma | - | - |
DCV/ASV/BMS-791325 | Phase 3 | Hepatitis C Virus | - | - |
Subcutaneous (SC) Abatacept | Phase 3 | Rheumatoid Arthritis (RA) | - | - |
Mezigdomide | Phase 3 | Relapsed or Refractory Multiple Myeloma | - | - |
Peginterferon Alfa-2a | Phase 3 | Hepatitis C | - | - |
Subcutaneous Abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
pexacerfont | Phase 3 | Generalized Anxiety Disorder | - | - |
Bempegaldesleukin | Phase 3 | Bladder Cancer | - | - |
Xanomeline/Trospium Chloride Capsule | Phase 3 | Alzheimer Disease | - | - |
current antiretroviral regimen | Phase 3 | HIV Infection | - | - |
ONO-4538 | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Iberdomide | Phase 3 | Multiple Myeloma | - | - |
emtricitabine, FTC (drug) | Phase 3 | HIV Infections | - | - |
Muraglitazar | Phase 3 | Metabolics Diabetes Nos | - | - |
Didanosine | Phase 3 | HIV Infections | - | - |
FOLFOX or | Phase 3 | Colorectal Cancer | - | - |
Deucravacitinib | Phase 3 | Psoriatic Arthritis | - | - |
Apixaban 5 MG | Phase 3 | Cancer-associated Thrombosis | - | - |
Mavacamten | Phase 3 | Cardiomyopathy, Hypertrophic | - | - |
clopidogrel (SR25990C) | Phase 3 | Atrial Fibrillation | - | - |
Cyclosporine A | Phase 3 | Renal Transplant | - | - |
Atazanvir/ritonavir + efavirenz | Phase 3 | HIV Infections | - | - |
Belatacept | Phase 3 | Renal Transplantation | - | - |
Lithium | Phase 3 | Bipolar Disorder Type I With Mania | - | - |
Asunaprevir (ASV) | Phase 3 | Hepatitis C Virus | - | - |
Methotrexate (MTX) | Phase 3 | Rheumatoid Arthritis (RA) | - | - |
Irbesartan/HCTZ | Phase 3 | Hypertension | - | - |
PEG-Interferon alfa 2a | Phase 3 | Hepatitis C, Genotype 1 | - | - |
Peginterferon Lambda-1a | Phase 3 | Hepatitis C Virus (HCV) | - | - |
atazanavir/ritonavir +2 NRTIs (immediate Switch Group) | Phase 3 | HIV Infections | - | - |
Double-blind Abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
Atazanavir powder | Phase 3 | HIV Infections | - | - |
Asunaprevir | Phase 3 | Hepatitis C | - | - |
Enteric Coated Mycophenolate Sodium | Phase 3 | Renal Allograft Recipients | - | - |
BMS-986165 | Phase 3 | Psoriasis | - | - |
KarXT | Phase 3 | Alzheimer Disease | - | - |
BMS-986353 | Phase 3 | Systemic Sclerosis | - | - |
Docetaxel/Paclitaxel | Phase 3 | Esophageal Cancer | - | - |
idecabtagene vicleucel | Phase 3 | Multiple Myeloma | - | - |
Warfarin titrated to an INR of 2.5-3.0 | Phase 3 | Heart Failure | - | - |
Glucovance (metformin HCl/glyburide) | Phase 3 | Diabetes Mellitus, Non-Insulin-Dependent | - | - |
ATV | Phase 3 | HIV Infections | - | - |
Topical Dapsone 5% Gel | Phase 3 | Cetuximab-induced Papulopustular (Acneiform) Rash Who Have | - | - |
Atazanavir/ritonavir monotherapy | Phase 3 | HIV-1 Infection | - | - |
DCV | Phase 3 | Hepatitis C | - | - |
Atazanavir+ritonavir | Phase 3 | HIV Infections | - | - |
Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa | Phase 3 | Breast Cancer | - | - |
DUAL | Phase 2 | Cirrhosis | - | - |
Oncovin | Phase 2 | Peripheral T Cell Lymphoma | - | - |
CRS-207 | Phase 2 | Previously Treated Metastatic Adenocarcinoma of the Pancreas | - | - |
IPI-549 (eganelisib) | Phase 2 | Bladder Cancer | - | - |
Degarelix | Phase 2 | Prostate Cancer | - | - |
CC-486 300 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
lulizumab pegol | Phase 2 | Living-Donor Kidney Transplant | - | - |
ECF | Phase 2 | Esophageal Cancer | - | - |
lisocabtagene maraleucel | Phase 2 | Lymphoma, Non-Hodgkin | - | - |
Xanomeline and trospium chloride (KarXT) | Phase 2 | SCHIZOPHRENIA 1 (Disorder) | - | - |
pemetrexed disodium | Phase 2 | Lung Cancer | - | - |
Androgen Deprivation Therapy | Phase 2 | Hormone Sensitive Prostate Cancer | - | - |
Plinabulin | Phase 2 | Lung Cancer | - | - |
GM-CSF (Sargramostim) | Phase 2 | Ovarian Cancer | - | - |
Dasatinib Maximum Tolerated Dose | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
Cetuximab,Paclitaxel, Carboplatin | Phase 2 | Esophageal Cancer | - | - |
UV1 vaccine + leukine | Phase 2 | Cancer | - | - |
CC-97540 | Phase 2 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | - | - |
HuMax-IL8 | Phase 2 | Head and Neck Squamous Cell Carcinoma | - | - |
golcadomide | Phase 2 | Follicular Lymphoma Stage II | - | - |
xenon gas | Phase 2 | Hypoxic Ischaemic Encephalopathy | - | - |
BMS- 986205 | Phase 2 | Endometrial Adenocarcinoma | - | - |
GVAX Pancreas Vaccine | Phase 2 | Pancreatic Cancer | - | - |
Bleomycin | Phase 2 | Hodgkin Lymphoma | - | - |
Varicella Zoster Vaccine | Phase 2 | Herpes Zoster | - | - |
IDO1 Inhibitor BMS-986205 | Phase 2 | Lip | - | - |
BMS-986249 | Phase 2 | Advanced Cancer | - | - |
Estramustine | Phase 2 | Prostate Cancer | - | - |
Fedratinib Pill | Phase 2 | Myeloproliferative Neoplasm | - | - |
pTVG-HP | Phase 2 | Prostate Cancer | - | - |
SipT Treatment | Phase 2 | Prostate Cancer | - | - |
Oral apixaban | Phase 2 | Gynecologic Cancer | - | - |
Vincristine Sulfate | Phase 2 | Aggressive Non-Hodgkin Lymphoma | - | - |
Drug Abilify | Phase 2 | Depression | - | - |
Neoantigen Dendritic Cell Vaccine | Phase 2 | Hepatocellular Carcinoma | - | - |
Pegylated Interferon alpha-2a | Phase 2 | Hepatitis C Virus Genotype 4 Infection | - | - |
Corticosteroid | Phase 2 | Heart Transplantation | - | - |
mFOLFIRINOX | Phase 2 | Phase 2 Study | - | - |
Chemotherapy, albumin-bound paclitaxel | Phase 2 | Glioblastoma | - | - |
Erbitux, Paclitaxel & Carboplatin | Phase 2 | Cancer of Head and Neck | - | - |
Corticosteroid: Betamethasone | Phase 2 | Melanoma | - | - |
Paclitaxel, vinorelbine, cisplatin | Phase 2 | NSCLC Stage IIIB | - | - |
pilimumab | Phase 2 | Advanced Stage Non-small Cell Lung Cancer | - | - |
roginolisib | Phase 2 | Peripheral T Cells Lymphoma (PTCL) | - | - |
Nulojix (Belatacept) | Phase 2 | Renal Transplant | - | - |
Clopidogrel 75 mg daily | Phase 2 | Atherosclerosis | - | - |
Testosterone cypionate | Phase 2 | Castration-resistant Prostate Cancer | - | - |
Dasatinib and Paclitaxel | Phase 2 | Breast Cancer | - | - |
TACE | Phase 2 | Carcinoma, Hepatocellular | - | - |
Low dose doxorubicin | Phase 2 | Metastatic Breast Cancer | - | - |
Tenofovir/emtricitabine | Phase 2 | HIV Infections | - | - |
gavo-cel | Phase 2 | Mesothelioma | - | - |
PD-1 blocking antibody | Phase 2 | Nasopharyngeal Carcinoma | - | - |
abatacept (Orencia ®) | Phase 2 | Urticaria | - | - |
BMS-754807 | Phase 2 | Breast Cancer | - | - |
Aurexis® | Phase 2 | Staphylococcus Aureus Bacteremia | - | - |
Vitamin K Antagonist (VKA) | Phase 2 | Thrombosis | - | - |
CXL-1020 | Phase 2 | Heart Failure | - | - |
Oral Taxane | Phase 2 | Non-small Cell Lung Cancer | - | - |
BMS-986253 | Phase 2 | Cancer | - | - |
Temozolomide 50mg/m2/day | Phase 2 | Adenocarcinoma - GEJ | - | - |
BMS-986322 | Phase 2 | Psoriasis | - | - |
BMS-986490 | Phase 2 | Advanced Solid Tumors | - | - |
MYK-491 | Phase 2 | Heart Failure With Reduced Ejection Fraction | - | - |
PSI-7977 | Phase 2 | Chronic Hepatitis C | - | - |
200 mg INX-08189 Fasted | Phase 2 | Hepatitis C | - | - |
unfractionated heparin (UFH) | Phase 2 | Antithrombotic | - | - |
MORAb-202 | Phase 2 | Neoplasms, Ovarian | - | - |
BMS-986523 | Phase 2 | Advanced Solid Malignancies | - | - |
BMS-986259 | Phase 2 | Acute Decompensated Heart Failure | - | - |
BMS-986036 | Phase 2 | Non-Alcoholic Steatohepatitis | - | - |
BMS-823778 | Phase 2 | Dyslipidemia | - | - |
Lirilumab | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
MDX-1100 | Phase 2 | Rheumatoid Arthritis | - | - |
BMS-986213 | Phase 2 | Advanced Solid Tumors | - | - |
Trametinib | Phase 2 | Cancer | - | - |
BMS-986158 | Phase 2 | Myelofibrosis | - | - |
BMS-986020 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
BMS-830216 | Phase 2 | Obesity | - | - |
Strata 1 CXL-1020 | Phase 2 | Heart Failure | - | - |
carboplatin + irinotecan | Phase 2 | Neoplasms | - | - |
BMS-986340 | Phase 2 | Cervical Cancer | - | - |
BMS-986446 | Phase 2 | Alzheimer Disease, Early Onset | - | - |
SAR302503 (TG101348) | Phase 2 | Myelofibrosis | - | - |
HNO Donor | Phase 2 | Heart Failure | - | - |
BMS-986435 | Phase 2 | Heart Failure | - | - |
ixabepilone | Phase 2 | Esophageal Cancer | - | - |
BMS-790052 | Phase 2 | Hepatitis C Infection | - | - |
BMS-986142 | Phase 2 | Rheumatoid Arthritis | - | - |
CC-92480 | Phase 2 | Multiple Myeloma | - | - |
Cabiralizumab | Phase 2 | Advanced Pancreatic Cancer | - | - |
CXL-1427 | Phase 2 | Heart Failure | - | - |
Peginterferon α-2a | Phase 2 | Hepatitis C | - | - |
BMS-986156 | Phase 2 | Solid Tumors | - | - |
MDX-010 / MDX-010 + Docetaxel | Phase 2 | Prostate Cancer | - | - |
Lamivudine | Phase 2 | Hepatitis B Virus | - | - |
BMS-986458 | Phase 2 | Relapsed/Refractory Non-Hodgkin Lymphoma | - | - |
Thymoglobulin | Phase 2 | Kidney Transplantation | - | - |
BMS-690514 | Phase 2 | Non-Small-Cell Lung Carcinoma | - | - |
Ritonavir | Phase 2 | HIV Infections | - | - |
Abatacept (BMS-188667) | Phase 2 | Rheumatoid Arthritis | - | - |
BMS-986288 | Phase 2 | Advanced Cancer | - | - |
BMS-650032 | Phase 2 | Hepatitis C Virus | - | - |
CC-486 | Phase 2 | Leukemia, Myeloid, Acute | - | - |
BMS-986141 | Phase 2 | Thrombosis | - | - |
Aurexis® (tefibazumab) | Phase 2 | Staphylococcus Aureus | - | - |
Cabazitaxel | Phase 2 | Prostate Cancer | - | - |
Pegylated Interferon Lambda | Phase 2 | Hepatitis C | - | - |
Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC) | Phase 2 | HIV Infections | - | - |
BMS-986369 | Phase 2 | Relapsed or Refractory T-cell Lymphomas | - | - |
5-fluorouracil (5-FU) | Phase 2 | Colorectal Cancer | - | - |
Peginterferon alpha-2a | Phase 2 | Hepatitis C Infection | - | - |
Exemestane + Dasatinib | Phase 2 | Breast Cancer | - | - |
Dasatinib 100 mg | Phase 2 | Breast Cancer | - | - |
MDX-010 | Phase 2 | Breast Cancer | - | - |
BMS-986004 75 mg IV | Phase 2 | Immune Thrombocytopenic Purpura | - | - |
Vemurafenib | Phase 2 | Melanoma | - | - |
KOS-1584 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
INX-08189 50 mg | Phase 2 | Healthy | - | - |
Pegylated-interferon alfa-2a | Phase 2 | Chronic Hepatitis C | - | - |
BMS-708163 | Phase 2 | Alzheimer's Disease | - | - |
BMS-954561 | Phase 2 | Diabetic Peripheral Neuropathic Pain | - | - |
CCR2 Antagonist | Phase 2 | Type 2 Diabetes | - | - |
BMS-986012 (anti-fucosyl-GM1) | Phase 2 | Small Cell Lung Cancer | - | - |
BMS-986482 | Phase 2 | Advanced Solid Tumors | - | - |
BMS-791325 | Phase 2 | Hepatitis C Virus | - | - |
BMS-562086 | Phase 2 | Irritable Bowel Syndrome | - | - |
Elotuzumab (BMS-901608) | Phase 2 | Multiple Myeloma | - | - |
BMS-986012 | Phase 2 | Extensive-stage Small Cell Lung Cancer | - | - |
BMS-833923 | Phase 2 | Leukemia | - | - |
BMS-986165 Dose A | Phase 2 | Active Psoriatic Arthritis | - | - |
BMS-986315 | Phase 2 | Advanced Solid Tumor | - | - |
BMS-986470 | Phase 2 | Anemia, Sickle Cell | - | - |
BMS-790052 (NS5A Inhibitor) | Phase 2 | Hepatitis C | - | - |
BMS-986525 | Phase 2 | Relapsed/Refractory Small Cell Lung Cancer | - | - |
BMS-813160 | Phase 2 | Advanced Cancer | - | - |
BMS-914392 | Phase 2 | Atrial Fibrillation | - | - |
branebrutinib | Phase 2 | Autoimmune Disorder | - | - |
Megestrol acetate | Phase 2 | Anorexia | - | - |
BMS-582949 | Phase 2 | Vascular Diseases | - | - |
Cobimetinib | Phase 2 | Microsatellite Unstable Colorectal Cancer | - | - |
Afimetoran | Phase 2 | Systemic Lupus Erythematosus | - | - |
BMS-820836 | Phase 2 | Depression | - | - |
pegIFN | Phase 2 | Hepatitis B Virus | - | - |
Thalidomide | Phase 2 | Relapsed and/or Refractory Multiple Myeloma | - | - |
BMS-986449 | Phase 2 | Advanced Solid Tumors | - | - |
Pegylated interferon alfa-2a | Phase 2 | Hepatitis C Virus | - | - |
Cyclosporine | Phase 2 | Graft Rejection | - | - |
Imzokitug | Phase 2 | Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | - | - |
Anti-CD137 (4-1BB) (BMS-663513) | Phase 2 | Melanoma | - | - |
BMS-777607 | Phase 2 | Advanced Solid Tumors | - | - |
Fedratinib | Phase 2 | Primary Myelofibrosis | - | - |
BMS-986231 | Phase 2 | Cardiac Failure | - | - |
BMS-908662 | Phase 2 | Colorectal Cancer | - | - |
BMS-770767 | Phase 2 | Diabetes Type 2 | - | - |
BMS-986507 | Phase 2 | Lung Cancer | - | - |
BMS-986263 | Phase 2 | Hepatic Cirrhosis | - | - |
INX-08189 50 mg QD X 5 days | Phase 2 | Healthy | - | - |
BMS-936557 (Anti-IP-10 Antibody) | Phase 2 | Crohn's Disease | - | - |
brivanib (active) | Phase 2 | Hepatocellular Carcinoma (HCC) | - | - |
MDX-010 (CTLA-4) | Phase 2 | Melanoma | - | - |
BMS-986207 | Phase 2 | Broad Solid Tumor | - | - |
BMS-986517 | Phase 2 | Solid Tumours | - | - |
Simeprevir | Phase 2 | Hepatitis C Virus | - | - |
CXCR1/2 Inhibitor SX-682 | Phase 2 | Metastatic Colon Adenocarcinoma | - | - |
BMS-986489 | Phase 2 | Limited Stage Small Cell Lung Cancer | - | - |
Carfilzomib | Phase 2 | Multiple Myeloma | - | - |
nab-Paclitaxel | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Dasatinib (BMS-354825) | Phase 2 | Leukemia | - | - |
APX005M | Phase 2 | Cancer | - | - |
Advanced Cancer
1 drug in this indication
Advanced melanoma with progression on anti-PD-1 therapy
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BRISTOL MYERS SQUIBB CO's drug pipeline?→
CatalystAlert tracks 288 drug candidates in BRISTOL MYERS SQUIBB CO's (CELG-RI) pipeline across Phase 3, Phase 2, Approved. Its lead program is Xanomeline/Trospium Chloride (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BRISTOL MYERS SQUIBB CO's next FDA catalyst?→
BRISTOL MYERS SQUIBB CO's (CELG-RI) next tracked catalyst is a Phase 2 expected September 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CELG-RI biotech catalysts?→
Add CELG-RI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BRISTOL MYERS SQUIBB CO's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.